دورية أكاديمية
أعرض في EDS

Impact of family history of prostate cancer on disease progression for prostatic cancer patients undergoing active surveillance: A systematic review and meta-analysis.

التفاصيل البيبلوغرافية
العنوان: Impact of family history of prostate cancer on disease progression for prostatic cancer patients undergoing active surveillance: A systematic review and meta-analysis.
المؤلفون: Jeon J; Department of Urology, Gangnam Severance Hospital, Seoul, Korea.; Urological Science Institute, Yonsei University College of Medicine, Seoul, Korea., Kim JH; Department of Urology, Soonchunhyang University Seoul Hospital, Soonchunhyang University College of Medicine, Seoul, Korea., Ha JS; Department of Urology, Gangnam Severance Hospital, Seoul, Korea.; Urological Science Institute, Yonsei University College of Medicine, Seoul, Korea., Yang WJ; Department of Urology, Soonchunhyang University Seoul Hospital, Soonchunhyang University College of Medicine, Seoul, Korea., Cho KS; Department of Urology, Gangnam Severance Hospital, Seoul, Korea.; Urological Science Institute, Yonsei University College of Medicine, Seoul, Korea., Kim DK; Department of Urology, Gangnam Severance Hospital, Seoul, Korea.; Urological Science Institute, Yonsei University College of Medicine, Seoul, Korea. dokyung80@yuhs.ac.
المصدر: Investigative and clinical urology [Investig Clin Urol] 2024 Jul; Vol. 65 (4), pp. 315-325.
نوع المنشور: Journal Article; Systematic Review; Meta-Analysis; Review
اللغة: English
بيانات الدورية: Publisher: Korean Urological Association Country of Publication: Korea (South) NLM ID: 101674989 Publication Model: Print Cited Medium: Internet ISSN: 2466-054X (Electronic) Linking ISSN: 24660493 NLM ISO Abbreviation: Investig Clin Urol Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Seoul : Korean Urological Association, [2016]-
مواضيع طبية MeSH: Prostatic Neoplasms*/genetics , Prostatic Neoplasms*/pathology , Disease Progression* , Watchful Waiting*, Humans ; Male
مستخلص: Purpose: To evaluate how a family history of prostate cancer influences the progression of the disease in individuals with prostate cancer undergoing active surveillance.
Materials and Methods: We conducted a thorough literature search in PubMed/MEDLINE, Embase, and Cochrane Library up to June 2023. This systematic review was registered in PROSPERO (CRD42023441853). The study evaluated the effects of family history of prostate cancer (intervention) on disease progression (outcome) in prostate cancer patients undergoing active surveillance (population) and compared them to those without a family history (comparators). For time to disease progression outcomes, the extracted data were synthesized using the inverse variance method on the log hazard ratios scale.
Results: A total of eight studies were incorporated into this systematic review and meta-analysis. The combined hazard ratio for unadjusted disease progression was 1.06 (95% confidential interval [CI] 0.66-1.69; p=0.82). The combined hazard ratio for adjusted disease progression was 1.31 (95% CI 1.16-1.48; p<0.0001). All the enlisted studies demonstrated high quality based on the Newcastle-Ottawa scale. The certainty of evidence for univariate and multivariate analysis of disease progression was very low and low, respectively. Publication bias for all studies was not significant.
Conclusions: For individuals with prostate cancer opting for active surveillance, a family history of prostate cancer may serve as an independent risk factor associated with an elevated risk of disease progression. Clinicians should be counseled about the increased risk of disease progression in patients with a family history of prostate cancer undergoing active surveillance.
Competing Interests: The authors have nothing to disclose.
(© The Korean Urological Association.)
References: Urol Int. 2022;106(12):1201-1213. (PMID: 36349773)
Can J Urol. 2021 Apr;28(2):10632-10637. (PMID: 33872564)
Prostate. 1990;17(4):337-47. (PMID: 2251225)
Eur Urol Oncol. 2023 Oct;6(5):493-500. (PMID: 37005213)
BJU Int. 2003 Jun;91(9):789-94. (PMID: 12780833)
Eur Urol. 2020 Jan;77(1):24-35. (PMID: 31495749)
J Urol. 2018 Mar;199(3):683-690. (PMID: 29203269)
BJU Int. 2013 Sep;112(5):666-73. (PMID: 23320731)
Eur Urol. 2022 Aug;82(2):163-169. (PMID: 34980493)
Nat Rev Urol. 2021 Apr;18(4):197-208. (PMID: 33623103)
Prostate Cancer Prostatic Dis. 2021 Sep;24(3):638-646. (PMID: 33589769)
J Clin Oncol. 2006 Jul 20;24(21):3445-50. (PMID: 16849760)
BMJ. 2003 Sep 6;327(7414):557-60. (PMID: 12958120)
JAMA. 2016 Jan 5;315(1):68-76. (PMID: 26746459)
J Clin Oncol. 2011 Sep 20;29(27):3669-76. (PMID: 21825257)
JAMA Oncol. 2019 Apr 01;5(4):523-528. (PMID: 30730552)
J Urol. 2023 Jun;209(6):1112-1119. (PMID: 36951811)
Contemp Clin Trials. 2007 Feb;28(2):105-14. (PMID: 16807131)
Nat Rev Urol. 2016 Apr;13(4):205-15. (PMID: 26954332)
J Urol. 2012 May;187(5):1594-9. (PMID: 22425088)
Urology. 2019 Aug;130:72-78. (PMID: 31029668)
Transl Androl Urol. 2018 Apr;7(2):243-255. (PMID: 29732283)
BMJ. 2008 Apr 26;336(7650):924-6. (PMID: 18436948)
World J Urol. 2018 Feb;36(2):177-185. (PMID: 29164326)
World J Urol. 2021 Jul;39(7):2499-2506. (PMID: 33048258)
N Engl J Med. 2000 Jul 13;343(2):78-85. (PMID: 10891514)
Ann Oncol. 2012 Jan;23(1):251-256. (PMID: 21467126)
Syst Rev. 2015 Jan 01;4:1. (PMID: 25554246)
BMC Cancer. 2019 Sep 2;19(1):871. (PMID: 31477094)
Eur Urol. 2017 Apr;71(4):618-629. (PMID: 27568654)
BJU Int. 2011 Mar;107(5):716-721. (PMID: 21166744)
J Urol. 2022 Aug;208(2):325-332. (PMID: 35377777)
J Urol. 2011 Feb;185(2):471-6. (PMID: 21167525)
J Natl Compr Canc Netw. 2023 Mar;21(3):236-246. (PMID: 36898362)
Eur Urol. 2023 Aug;84(2):191-206. (PMID: 37202314)
Urology. 2015 Apr;85(4):742-7. (PMID: 25709045)
BJU Int. 2017 Oct;120(4):464-467. (PMID: 28371016)
Stat Med. 1998 Dec 30;17(24):2815-34. (PMID: 9921604)
فهرسة مساهمة: Keywords: Active surveillance; Disease progression; Hereditary prostate cancer; Meta-analysis; Prostate neoplasms
تواريخ الأحداث: Date Created: 20240709 Date Completed: 20240709 Latest Revision: 20240711
رمز التحديث: 20240711
مُعرف محوري في PubMed: PMC11231664
DOI: 10.4111/icu.20240053
PMID: 38978211
قاعدة البيانات: MEDLINE
الوصف
تدمد:2466-054X
DOI:10.4111/icu.20240053